Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 3/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.30 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.30 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3832798 | 1.00 | ITGB1 (0.38) | ITGB1ITGA4CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL3833845 | 0.88 | ITGB1 (0.38) | ITGB1ITGA4 | |
| SCHEMBL5574152 | 0.86 | ITGB1 (0.42) | ITGB1ITGA4 | |
| SCHEMBL5148512 | 0.85 | ITGB1 (0.37) | ITGB1ITGA4 | |
| SCHEMBL3833793 | 0.83 | ITGB1 (0.38) | ITGB1ITGA4 | |
| SCHEMBL2978998 | 0.82 | ITGB1 (0.55) | ITGB1ITGA4 | |
| SCHEMBL5575175 | 0.82 | ITGB1 (0.55) | ITGB1ITGA4 | |
| SCHEMBL5149368 | 0.82 | ITGB1 (0.34) | ITGB1ITGA4CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL3836800 | 0.80 | ITGB1 (0.34) | ITGB1ITGA4 | |
| SCHEMBL5148458 | 0.80 | KDR (0.32) | ITGB1ITGA4CSNK2A1CSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951943-B2 | Process for the preparation of phenylalanine enamide derivatives | CELLTECH R & D LIMITED (GB) | 2005-10-04 | — | — | US | disclosed |
| US-20040073033-A1 | Process for the preparation of phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073033-A1 | Process for the preparation of phenylalanine enamide derivatives | NPY2R, NPY1R, NPR1 | ITGB1 4148/4885ITGA4 3960/4885CSNK2A1 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.